Visioneering Technologies, Inc. (VTI) announced new scientific findings and clinical insights presented this week at the Global Specialty Lens Symposium (GSLS), reinforcing how NaturalVue® (etafilcon A) Multifocal is designed to support myopia management in real-world pediatric populations—and how clinicians can translate data into everyday practice.

New Scientific Findings: PROTECT 2-Year Data and Risk Factor Analysis

New analyses from the ongoing PROTECT randomized clinical trial were presented in both a scientific poster and podium session by Ashley Tuan, OD, PhD, FAAO, evaluating how clinical, familial, and social risk factors influence myopia progression—and how treatment modifies their impact.¹

Key findings included:

  • Over two years, children aged 8–12 treated with NaturalVue® Multifocal showed significantly lower myopia progression versus single-vision contact lenses:
    • 0.59 D less refractive progression
    • 0.22 mm less axial elongation
  • Machine-learning analyses identified age as the strongest driver of progression under natural history, while treatment with NaturalVue® Multifocal reduced the overall impact of known risk factors by approximately 45–58%
  • Treatment effects were consistent across age, sex, pupil size, familial, and lifestyle variables, indicating age of initiation did not meaningfully alter efficacy
  • Under natural progression, females demonstrated faster progression than males; this sex-based risk factor was minimized in children wearing NaturalVue® Multifocal

“These results reinforce what we see clinically—that myopia progression is influenced by many factors outside a clinician’s control,” said Dr. Tuan, “The PROTECT data show that NaturalVue® Multifocal helps reduce the impact of that variability, allowing practitioners to focus on what they can control: early intervention, consistent wear, and predictable outcomes—while still letting kids be kids in today’s real-world environments.”

Putting the Data to Work: Built for Real Life in Clinical Practice

In a separate GSLS presentation, Brett O’Connor, OD, FAAO, shared how these data translate into day-to-day patient care.

Practice-focused takeaways included:

  • One lens, more applications: A single catenary optical design supports myopia management, presbyopia, and many astigmatic patients—simplifying fitting decisions in busy practices
  • Visual performance aligned with real life: By extending depth of focus rather than relying on discrete focal zones, the Neurofocus Optics® design supports functional distance, intermediate, and near vision across life stages
  • Astigmatism performance that matters: Clinical data demonstrate strong visual acuity outcomes in patients with up to 3.00 D of astigmatism, without requiring a toric lens²
  • Designed for real practices: Straightforward fitting and intuitive on-eye adjustments reduce chair time and troubleshooting, making the lens practical for routine use across a broad range of patients

“In my practice, these features translate into easier adaptation and consistent vision quality for patients,” said Dr. O’Connor. “That helps patients succeed in real-world settings and gives clinicians confidence in predictable outcomes.”

About PROTECT

‘PROTECT’ (PROgressive Myopia Treatment Evaluation for NaturalVue Multifocal Contact Lens Trial) is a 3-year, prospective, double-masked multi-national trial evaluating the safety & effectiveness of NaturalVue® Multifocal Contact Lenses for slowing myopia progression (participating investigators in the United States, Canada, Hong Kong, and Singapore) involving 145 children. This information reflects the 2 Year data set myopia management results (treatment group) plus the analysis of the complete 3-year study where the control group was crossed over. Adjusted data, equalized for key variables such as age, sex, and pupil size. Data reflects Planned Subgroup ages 8-12 and power range of -0.75 to -4.00.

About Visioneering Technologies

Visioneering Technologies Inc. is an innovative eye care company focused on redefining vision through advanced optical design. Its flagship product, NaturalVue® (etafilcon A) Multifocal 1 Day Contact Lens, features a proprietary extended depth of focus design intended to support vision correction across myopia, presbyopia, and astigmatism.

This information may describe uses for this product, including myopia progression control, that have not been approved by the FDA for use in the United States. It is intended for educational purposes only. NaturalVue® Multifocal is part of an ongoing randomized clinical trial (PROTECT).

References

  1. Tuan A, Novak S, Dillehay S, PROTECT Study Group. Clinical, familial, and social risk factors for myopia progression: learnings from the PROTECT 2-year data. Poster presented at Global Specialty Lens Symposia; January 8, 2026; Las Vegas, NV.
  2. Tuan A. New Evidence Uncovered: 2-Year RCT Findings in Myopia Management, Astigmatism, and Vision Outcomes with NaturalVue. Presented at American Academy of Optometry; October 10, 2025; Boston, MA. Astigmatism study conducted by Carracedo G., Universidad Complutense de Madrid, Spain.

VTI-RCT-PR11



Get the latest Optical News delivered to you. Click here to subscribe to our FREE print magazine and weekly newsletter